Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 1 - 20 ( 260 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Bot/Bal Neoadjuvant CRC Update at ESMO GI Indicates Deeper Pathological Responses
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstract Highlights Sub-Analysis of Bot/Bal Potential for Broad Benefit in MSS-CRC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: MSS-CRC Regulatory Discussions and Key Bot/Bal Phase 2 Data Readouts Expected in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: 2024 to Mark a Pivotal Year For Agenus With Potential First Bot/Bal BLA Filing
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Multiple Data Readouts and BLA Filings Anticipated in 2024; Potential Bot/Bal Partnership on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
ESMO Data Updates Validate That Agenus Could Be the Next Big IO Play
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Next Significant Catalyst Could Be NSCLC Data Update in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Bot/Bal Phase 1b OS Data Impress in MSS-CRC Patients, Increasing Our Confidence in Phase 2 Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
AGEN2373 Data Surprise to the Upside; Gotistobart Data Validate CTLA-4 Efficacy in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Take: Pipeline Progress Continues With Multiple Data Presentations and Study Initiations on Track for 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Bot/Bal Combination Continues to Demonstrate Responses in Ovarian Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: Botensilimab Continues to Demonstrate Positive Results in Cold Tumors With NSCLC Taking the Stage
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Botensilimab Could be the Next Big IO Play; Assuming at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Agenus Reported FY2021 Results; 2022 May Be An Inflection Year; Reiterate Buy and Increase PT from $12 to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Is Agenus the Most Under the Radar Biotech in I/O? Initiate at Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department